-

APLS Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Investors

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS).

On July 17, 2023, the American Society of Retina Specialists issued a press release highlighting concerns with Syfovre, Apellis Pharmaceuticals’ new eye-disease drug. The release indicated that physicians have reported cases of eye inflammation in patients treated with the drug, including six instances of occlusive retinal vasculitis, a potentially blinding type of inflammation that blocks blood flow through the vessels that feed the retina.

Following this news, Apellis Pharmaceuticals’ stock price plummeted 37.9%, to close at $52.46 on July 17, 2023.

If you are an Apellis Pharmaceuticals investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at info@ktmc.com. You can also click on the following link or paste it in your browser: https://www.ktmc.com/apellis-pharmaceuticals-inc-investigation?utm_source=PR&utm_medium=link&utm_campaign=apls&mktm=r

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.

Contacts

Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com

Kessler Topaz Meltzer & Check, LLP

NASDAQ:APLS

Release Versions

Contacts

Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com

More News From Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP Files a Class Action Lawsuit Against Volkswagen for Selling Vehicles With Defective Batteries that Catch Fire

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized class action litigation law firm, has filed a class action lawsuit against Volkswagen Aktiengesellschaft and Volkswagen Group of America, Inc. (“VW”), for breach of express warranty and other federal and state law violations. The complaint alleges that VW manufactured and sold certain vehicles – 2023-2025 Volkswagen ID.4s – which have defective batteries that may suddenly and unexpectedl...

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant financial losses. Alnylam Reports Disappointing Financial Results On July 30, 2026, Alnylam announced its second quarter 20...

Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

RADNOR, Pa.--(BUSINESS WIRE)--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Capricor Therapeutics, Inc. (Capricor) (NASDAQ: CAPR) on behalf of those who purchased or acquired Capricor securities between December 17, 2025 and July 26, 2026, inclusive. The lawsuit is filed in the United States District Court for the Southern District of California...
Back to Newsroom